Samso News is all about Making News Simple. Our strategy is now to make the Samso platform a one-stop shop for companies and potential investors to come and find independent and balanced insights on ASX stories.

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has unveiled compelling Phase 2 clinical trial data for its lead drug candidate, ATH434—a major advancement in treating Multiple System Atrophy (MSA). The findings were presented at the prestigious European MSA Symposium in London, drawing attention from global experts in neurodegenerative research.